Enterprise value of Supernus Pharmaceuticals, Inc.
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. The company's product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD. It also develops SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.
|CHKE Cherokee Inc.||NASDAQ > Consumer Non-Durables > Apparel||4.89|
|CAR Avis Budget Group, Inc.||NASDAQ > Consumer Services > Rental/Leasing Companies||4.89|
|PBPB Potbelly Corporation||NASDAQ > Consumer Services > Restaurants||4.89|
|INFN Infinera Corporation||NASDAQ > Public Utilities > Telecommunications Equipment||4.90|
|KRYS Krystal Biotech, Inc.||NASDAQ > Health Care > Biotechnology: Biological Products (No Diagnostic Substances)||4.90|
|WMS Advanced Drainage Systems, Inc.||NYSE > Capital Goods > Containers/Packaging||4.91|
|SUPN Supernus Pharmaceuticals, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||4.91|
|PCO Pendrell Corporation||NASDAQ > Miscellaneous > Multi-Sector Companies||879.05|
|WTM White Mountains Insurance Group, Ltd.||NYSE > Finance > Property-Casualty Insurers||938.42|
|DCIX Diana Containerships Inc.||NASDAQ > Transportation > Marine Transportation||1,903.21|
|SEB Seaboard Corporation||NYSEMKT > Finance > Investment Bankers/Brokers/Service||2,890.09|
|BRK-A Berkshire Hathaway Inc.||NYSE > Finance > Property & Casualty Insurance||187,384.70|
|BRK-B Berkshire Hathaway Inc.||NYSE > Finance > Property & Casualty Insurance||187,384.70|